Quantcast Alba Therapeutics in Washington Post | NFCA
Skip Navigation Links

Alba Therapeutics in Washington Post


A new research study presented at the Digestive Disease Week meeting in San Diego found that a medicine called AT-1001 may protect celiac disease patients from exposure to gluten by preventing gluten from crossing the intestinal mucosa. In a second study at the meeting, researchers concluded that the current criteria for diagnosing celiac is too stringent, resulting in many patients going undiagnosed and untreated.

  • Have you or your family members been diagnosed?
    Complete our celiac disease symptoms checklist today to find out if you are at risk of having celiac disease or non-celiac gluten sensitivity ('gluten sensitivity').  We can help improve your quality of life!
  • Stay Informed!
    Join our monthly newsletter to receive news, updates, and tips for healthy gluten-free living and information about celiac disease. Sign-up for the monthly e-mail newsletter